Biography: Rebecca Obeng, MD, PhD
Titles
- Assistant Professor, CWRU School of Medicine
Education
Research Fellowship | Gastrointestinal Pathology
Gastrointestinal Pathology - Emory University School Of Medicine (2018 - 2020)
Residency | Anatomic Pathology
Anatomic Pathology - Emory University Hospital (2015 - 2018)
Internship | General Surgery
General Surgery - University Of Colorado Anschutz Medical Campus (2014 - 2015)
Other Education
Harvard School Of Public Health (2013 - 2014)
Medical Education
University Of Virginia School Of Medicine (2013)
Other Education
University Of Virginia School Of Medicine (2011)
Undergraduate
Virginia Polytechnic Institute And State University (2003)
About
Rebecca Obeng, MD, PhD, MPH joins the University Hospitals Department of Pathology and specializes in gastrointestinal and liver pathology. Dr. Obeng received her Bachelors of Science in Biology and Psychology from Virginia Tech, followed by her Doctorates of Medicine and Philosophy from the University Of Virginia School Of Medicine. She completed her residency and fellowship training at Emory University.
Dr. Obeng is a tumor immunologist and her current research aims to elucidate T cell differentiation and function in the tumor microenvironment and to develop immunotherapeutic strategies for patients with cancer. She has published her work in peer-review journals, presented at numerous conferences and has two patents. Dr. Obeng has received funding from sources including the National Cancer Institute and American Lung Association. She is also the Chief Executive Officer of a non-profit organization, Sub-Saharan Africa Healthcare Initiative that works to improve anatomic pathology and laboratory services in Africa.
Dr. Obeng has a rich history of leadership experience and community and volunteer service. She has also received several awards including Emory University 40 under Forty Honoree and the American Society for Clinical Pathology 40 under Forty in Pathology Honoree.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Rebecca Obeng did not disclose any Outside Relationships with Industry.